Medpace Holdings, Inc. Common Stock (MEDP) — Analysis Summary
Medpace Holdings, Inc. Common Stock (MEDP) has a market cap of $16.77B with year-over-year revenue growth of +20.0%. Net margin stands at 17.8%. The stock trades at a P/E ratio of 34.1.
Key Takeaways
- Revenue changed +20.0% year-over-year
- Net margin of 17.8%
- P/E ratio of 34.1
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, MEDP posted revenue growth of +20.0% and trades at a P/E of 34.1.
Medpace Holdings, Inc. Common Stock (MEDP)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.73x — current liabilities exceed current assets
Operating margin (21.0%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
6,500
Headquarters
CINCINNATI, OH
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.